Results 91 to 100 of about 2,000 (177)

HIV-1 capsid stability and reverse transcription are finely balanced to minimize sensing of reverse transcription products via the cGAS-STING pathway

mBio
A critical determinant for early post-entry events, the HIV-1 capsid (CA) protein forms the conical core when it rearranges around the dimeric RNA genome and associated viral proteins.
Jenna E. Eschbach, Maritza Puray-Chavez, Shawn Mohammed, Qiankun Wang, Ming Xia, Lin-Chen Huang, Liang Shan, Sebla B. Kutluay   +7 more
doaj   +1 more source

Investigation of Natural Resistance to Fostemsavir and Lenacapavir in Naïve Primary Infections by Ultra-Deep Sequencing of near Full-Length HIV-1 Genomes

Viruses
Next-generation sequencing (NGS) of near full-length HIV genomes was performed to investigate natural resistance to Fostemsavir (FTR) and Lenacapavir (LEN) at the quasispecies level in nine naïve primary HIV infections harboring different HIV subtypes ...
Elisabetta Lazzari, Gabriella Rozera, Roberta Gagliardini, Valentina Mazzotta, Lavinia Fabeni, Federica Forbici, Giulia Berno, Cristian Cosentino, Enrico Girardi, Andrea Antinori, Fabrizio Maggi, Isabella Abbate   +11 more
doaj   +1 more source

Sustained virologic suppression of multidrug-resistant HIV in an individual treated with anti-CD4 domain 1 antibody and lenacapavir

Nature Medicine
The clinical management of people with multidrug-resistant (MDR) human immunodeficiency virus (HIV) remains challenging despite continued development of antiretroviral agents. A 58-year-old male individual with MDR HIV and Kaposi sarcoma (KS) was treated
M. Rai, J. Blazkova, L. Kardava, J. Justement, Victoria Shi, Maegan R. Manning, A. Shahid, W. Dong, Brooke D. Kennedy, Adeline B Sewack, Jeanette Higgins, C. Buckner, Kathleen R. Gittens, Raymond E. West, A. Devanathan, R. Mangusan, K. Lurain, R. Ramaswami, R. Yarchoan, M. Sneller, Alice K. Pau, Z. Brumme, S. Moir, Tae-Wook Chun   +23 more
semanticscholar   +1 more source

Lenacapavir-induced capsid damage uncovers HIV-1 genomes emanating from nuclear speckles

The EMBO Journal
Following cell entry, HIV-1 capsids enter the nucleus by passage through nuclear pores and reach nuclear speckles with subsequent uncoating of the reverse-transcribed genome and its integration into speckle-associated chromatin domains.
Thorsten G Müller, Severina Klaus, Vojtech Zila, Bojana Lucic, Carlotta Penzo, Svenja L Nopper, Gonen Golani, Maria Anders-Össwein, Vera Sonntag-Buck, Anke-Mareil Heuser, Ulrich S Schwarz, Vibor Laketa, Marina Lusic, Barbara Müller, Hans-Georg Kräusslich   +14 more
doaj   +1 more source

155. Long-Acting Subcutaneous Lenacapavir in People with Multi-Drug Resistant HIV-1: 3-Year Results of the CAPELLA Study

Open Forum Infectious Diseases
Background Lenacapavir (LEN) is a highly potent, long-acting HIV-1 capsid inhibitor approved in combination with other antiretrovirals (ARVs), for the treatment of heavily treatment-experienced (HTE) people with HIV-1 (PWH) with multidrug resistance (MDR)
O. Ogbuagu, J. McGowan, Ann Stapleton, A. Wiznia, Daniel S. Berger, C. Creticos, D. Hagins, O. Osiyemi, James Sims, David A Wheeler, Hui Wang, N. Margot, H. Dvory‐Sobol, Martin S Rhee, Sorana Segal-Maurer   +14 more
semanticscholar   +1 more source

Lack of Resistance Mutations to the Novel HIV-1 Capsid Inhibitor Lenacapavir Among People Living with HIV in Guangdong, China

Infection and Drug Resistance
Yaqing Lin,1,* Xuemei Ling,2,3,* Linghua Li,2,* Ruolei Xin,4 Fengyu Hu,1 Junbin Li,3 Jiaojiao Li,1 Feng Li,1,5 Yun Lan1 1Institute of Infectious Diseases, Guangzhou Eighth People’s Hospital, Guangzhou Medical University, Guangzhou, People’s ...
Lin Y, Ling X, Li L, Xin R, Hu F, Li J, Li J, Li F, Lan Y   +8 more
doaj  

Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at Baseline

Open Forum Infectious Diseases
ARTISTRY-1 is a phase 2/3 trial of bictegravir (BIC; 75 mg) plus lenacapavir (LEN; 25 mg or 50 mg) versus complex antiretroviral therapy regimens in 128 virologically suppressed people with HIV-1.
K. Mounzer, Jihad Slim, M. Ramgopal, Malcolm Hedgcock, Mark Bloch, Jorge Santana, Keith Aizen, Xu Zhang, Peter Sklar, J. M. Montezuma-Rusca, Sorana Segal-Maurer   +10 more
semanticscholar   +1 more source

A Scientometric Mapping of Global Lenacapavir and HIV Research: Dynamism, Visualization, and Emerging Patterns

Background: Lenacapavir, an HIV capsid inhibitor, has shown powerful promise for HIV treatment and prevention purposes.
Miguel Cabanillas-Lazo, Fran Espinoza-Carhuancho, Lucia Quispe-Tasayco, Julia Medina, Frank Mayta-Tovalino, Cesar Mauricio-Vilchez   +5 more
core   +1 more source

Natural occurrence of drug resistance mutations to the HIV‐1 capsid inhibitor lenacapavir

HIV Medicine
Lenacapavir (LEN) is a first‐in‐class HIV‐1 capsid inhibitor. We investigated the natural occurrence of LEN drug resistance mutations (DRM) in HIV‐1 sequences from LEN treatment‐naïve individuals.
A. W. Wärnberg, R. Ceña-Diez, A. Sönnerborg, M. V. D. van de Klundert   +3 more
semanticscholar   +1 more source

Abstracts From AIDS 2026, the 26th International AIDS Conference, 26 – 31 July 2026 Rio de Janeiro, Brazil & virtual

Journal of the International AIDS Society, Volume 29, Issue S4, July 2026.
wiley   +1 more source